Citations

Clear

187 citation(s) found for "Ha, Gavin".

Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity
Hartnett, M. Elizabeth , Bretz, Colin A. , Hann, Cheryl R., Cui, Ricky Z. , Marmorstein, Alan D. , Sheikh‐Hamad, David , Fautsch, Michael P. , Roddy, Gavin W. , Roddy, Gavin W , Dalvin, Lauren A. , Hartnett, M. Elizabeth , Marmorstein, Alan D

Mayo Clinic

Current Eye Research | July 17, 2019 | Volume: 45 | Issue: 1 | Pages: 46-51

10.1080/02713683.2019.1645184 | PMID 31314602 Get It

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)
Topp, Max S. , Arnason, Jon , Brown, Jennifer R. , Allan, John N. , Ansell, Stephen M. , Duell, Johannes , Rosenwald, Andreas , Charnas, Robert L., Ambati, Srikanth, Adriaens, Lieve, Ufkin, Melanie, Li, J. , Gasparini, Peter, Janković, Vladimir , Fiaschi, Nathalie , Zhang, W., Hamon, Sara , Yancopoulos, George D., Lowy, Israel , Sternberg, David , Advani, Ranjana H. , O’Brien, Susan , Chavez, Julio C , Zhu, Min , Thurston, Gavin , Murphy, Andrew James , Bannerji, Rajat

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 90-92

10.1002/hon.58_2629 Get It

Short-term Calorie Restriction and 17α-Estradiol Administration Elicit Divergent Effects on Proteostatic Processes and Protein Content in Metabolically Active Tissues
Miller, Benjamin F. , Pharaoh, Gavin , Hamilton, Karyn L. , Peelor, Fredrick F., Kirkland, James L. , Freeman, Willard M. , Mann, Shivani N. , Price, John C. , Freeman, Willard M , Kinter, Michael T , Stout, Michael B

Mayo Clinic

The Journals of Gerontology: Series A | May 10, 2019 | Volume: 75 | Issue: 5 | Pages: 849-857

10.1093/gerona/glz113 | PMID 31074767 Get It

Abstract17α-Estradiol (17α-E2) is a “non-feminizing” estrogen that extends life span in male, but not female, mice. We recently reported that 17α-E2 had robust beneficial effects on metabolic and inflammatory parameters in aged male mice. However, it remains unclear if 17α-E2 also delays other “hallmarks” of aging, particularly maintaining proteostasis. Here, we used isotope labeling methods in older mice to examine proteostatic mechanisms. We compared weight-matched mild calorie restricted (CR) and 17α-E2 treated male mice with the hypothesis that 17α-E2 would increase protein synthesis for somatic maintenance. 17α-E2 had no effect on protein synthesis or DNA synthesis in multiple tissues, including white adipose tissue. Conversely, mild short-term CR decreased DNA synthesis and increased the protein to DNA synthesis ratio in multiple tissues. Examination of individual protein synthesis and content did not differentiate treatments, although it provided insight into the regulation of protein content between tissues. Contrary to our hypothesis, we did not see the predicted differences in protein to DNA synthesis following 17α-E2 treatment. However, mild short-term CR elicited differences consistent with both lifelong CR and other treatments that curtail aging processes. These data indicated that despite similar maintenance of body mass, 17α-E2 and CR treatments elicit distinctly different proteostatic outcomes.
Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction
Walaszczyk, Anna , Dookun, Emily , Redgrave, Rachael E. , Tual‐Chalot, Simon , Victorelli, Stella , Spyridopoulos, Ioakim , Owens, W. Andrew , Arthur, Helen M. , Passos, João F. , Richardson, Gavin D. , Spyridopoulos, Ioakim , Arthur, Helen M , Passos, João F , Richardson, Gavin D

Mayo Clinic

Aging Cell | March 28, 2019 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/acel.12945 | PMID 30920115 Get It

Abstract Cardiovascular disease is the leading cause of death in individuals over 60 years old. Aging is associated with an increased prevalence of coronary artery disease and a poorer prognosis following acute myocardial infarction (MI). With age, senescent cells accumulate in tissues, including the heart, and contribute to age‐related pathologies. However, the role of senescence in recovery following MI has not been investigated. In this study, we demonstrate that treatment of aged mice with the senolytic drug, navitoclax, eliminates senescent cardiomyocytes and attenuates profibrotic protein expression in aged mice. Importantly, clearance of senescent cells improved myocardial remodelling and diastolic function as well as overall survival following MI. These data provide proof‐of‐concept evidence that senescent cells are major contributors to impaired function and increased mortality following MI and that senolytics are a potential new therapeutic avenue for MI.
RNA‐Seq detects a SAMD12‐EXT1 fusion transcript and leads to the discovery of an EXT1 deletion in a child with multiple osteochondromas
Oliver, Gavin R. , Blackburn, Patrick R. , Ellingson, Marissa S. , Conboy, Erin , Vairo, Filippo Pinto e , Webley, Matthew, Thorland, Erik C., Ferber, Matthew J. , Hul, Els Van, Werf, Ilse M. van der, Babovic‐Vuksanovic, Dusica , Klee, Eric W. , Pinto E Vairo, Filippo, Thorland, Erik, Ferber, Matthew, Babovic-Vuksanovic, Dusica, Vairo, Filippo , Wuyts, Wim A.

Mayo Clinic

Molecular Genetics & Genomic Medicine | January 11, 2019 | Volume: 7 | Issue: 3 | Pages: No page available

10.1002/mgg3.560 | PMID 30632316 Get It

AbstractBackgroundWe describe a patient presenting with pachygyria, epilepsy, developmental delay, short stature, failure to thrive, facial dysmorphisms, and multiple osteochondromas.MethodsThe patient underwent extensive genetic testing and analysis in an attempt to diagnose the cause of his condition. Clinical testing included metaphase karyotyping, array comparative genomic hybridization, direct sequencing and multiplex ligation‐dependent probe amplification and trio‐based exome sequencing. Subsequently, research‐based whole transcriptome sequencing was conducted to determine whether it might shed light on the undiagnosed phenotype.ResultsClinical exome sequencing of patient and parent samples revealed a maternally inherited splice‐site variant in the doublecortin (DCX) gene that was classified as likely pathogenic and diagnostic of the patient's neurological phenotype. Clinical array comparative genome hybridization analysis revealed a 16p13.3 deletion that could not be linked to the patient phenotype based on affected genes. Further clinical testing to determine the cause of the patient's multiple osteochondromas was unrevealing despite extensive profiling of the most likely causative genes, EXT1 and EXT2, including mutation screening by direct sequence analysis and multiplex ligation‐dependent probe amplification. Whole transcriptome sequencing identified a SAMD12‐EXT1 fusion transcript that could have resulted from a chromosomal deletion, leading to the loss of EXT1 function. Re‐review of the clinical array comparative genomic hybridization results indicated a possible unreported mosaic deletion affecting the SAMD12 and EXT1 genes that corresponded precisely to the introns predicted to be affected by a fusion‐causing deletion. The existence of the mosaic deletion was subsequently confirmed clinically by an increased density copy number array and orthogonal methodologiesConclusionsWhile mosaic mutations and deletions of EXT1 and EXT2 have been reported in the context of multiple osteochondromas, to our knowledge, this is the first time that transcriptomics technologies have been used to diagnose a patient via fusion transcript analysis in the congenital disease setting.
Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice
Correia‐Melo, Clara , Birch, Jodie , Fielder, Edward , Rahmatika, Dina , Taylor, Jennifer, Chapman, James , Lagnado, Anthony B. , Carroll, Bernadette , Miwa, Satomi , Richardson, Gavin D. , Jurk, Diana , Oakley, Fiona , Mann, Jelena , Mann, Derek A. , Passos, João F. , Lagnado, Anthony, Jurk, Diana , Passos, João F , Richardson, Gavin D , Taylor, Jennifer, Korolchuk, Viktor I.

Mayo Clinic

Aging Cell | November 23, 2018 | Volume: 18 | Issue: 1 | Pages: No page available

10.1111/acel.12882 | PMID 30468013 Get It

AbstractIncreased activation of the major pro‐inflammatory NF‐κB pathway leads to numerous age‐related diseases, including chronic liver disease (CLD). Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF‐κB signalling. However, it is unknown if rapamycin has beneficial effects in the context of compromised NF‐κB signalling, such as that which occurs in several age‐related chronic diseases. In this study, we investigated whether rapamycin could ameliorate age‐associated phenotypes in a mouse model of genetically enhanced NF‐κB activity (nfκb1−/−) characterized by low‐grade chronic inflammation, accelerated aging and CLD. We found that, despite showing no beneficial effects in lifespan and inflammaging, rapamycin reduced frailty and improved long‐term memory, neuromuscular coordination and tissue architecture. Importantly, markers of cellular senescence, a known driver of age‐related pathology, were alleviated in rapamycin‐fed animals. Our results indicate that, in conditions of genetically enhanced NF‐κB, rapamycin delays aging phenotypes and improves healthspan uncoupled from its role as a suppressor of inflammation.
Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults
Kudva, Yogish C. , Ahmann, Andrew , Bergenstal, Richard M. , Gavin, James R. , Kruger, Davida , Midyett, L. Kurt , Miller, Eden , Harris, Dennis R. , Ahmann, Andrew J , Kruger, Davida F

Mayo Clinic

Journal of the Endocrine Society | November 14, 2018 | Volume: 2 | Issue: 12 | Pages: 1320-1337

10.1210/js.2018-00294 | PMID 30474069 Get It

Synovial Cyst Direct Puncture, Overpressurization, and Rupture Under Fluoroscopy
Kim, Dong Kun , McKenzie, Gavin , McKenzie, Gavin A

Mayo Clinic

Pain Medicine | October 24, 2018 | Volume: 20 | Issue: 3 | Pages: 575-577

10.1093/pm/pny264 | PMID 30561735 Get It

Accessory Sacroiliac Joint Injection for Relief of Buttock Pain
Kim, Dong Kun , McKenzie, Gavin , McKenzie, Gavin A

Mayo Clinic

Pain Medicine | October 19, 2018 | Volume: 20 | Issue: 2 | Pages: 412-413

10.1093/pm/pny254 | PMID 30624698 Get It

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.
Borazanci, Erkut , Jameson, Gayle , Downes, Michael , Truitt, Morgan , Patel, Hitendra , Lowy, Andrew M. , Roe, Denise J. , Ansaldo, Karen, Barrett, Michael T. , Korn, Ronald L. , Caldwell, Lana, Slethaug, Gavin, Hultsch, Rolf, Han, Haiyong , Engelthaler, David M. , Lenkiewics, Elizabeth, Hoff, Daniel D. Von , Borazanci, Erkut , Chung, Vincent , Evans, Ronald M. , Patel, Hitendra, Pearson, Talima

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4154-TPS4154

10.1200/jco.2018.36.15_suppl.tps4154 Get It